Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics
- Tolerability and proof-of-mechanism for lead candidate AVB-S6-500, a novel GAS6-AXL pathway inhibitor, established in ongoing Phase 1 clinical study - Multi-study clinical development program in combination with standard of care therapies in tumor types overexpressing GAS6-AXL expected to begin
View HTML
Toggle Summary Versartis Reports First Quarter 2018 Financial Results
MENLO PARK, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc . (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018 . “We have undertaken additional efforts to aggressively manage our cash as we work
View HTML
Toggle Summary Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
MENLO PARK, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc . (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2017 , and provided a corporate update.
View HTML
Toggle Summary Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions
MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced that it has retained Cowen to assist in evaluating possible strategic transactions. The process is aimed at identifying opportunities to diversify the
View HTML
Toggle Summary Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update
MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc . (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2017, and provided a corporate update. "In response to the disappointing outcome of the
View HTML
Toggle Summary Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint
MENLO PARK, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that the
View HTML
Toggle Summary Versartis' Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017
MENLO PARK, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that somavaratan
View HTML
Toggle Summary Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs
MENLO PARK, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the
View HTML
Toggle Summary Versartis to Present at the Canaccord Genuity Growth Conference
MENLO PARK, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that Jay
View HTML
Toggle Summary Versartis Reports Second Quarter 2017 Financial Results
Confirms Phase 3 Data Expected Late September
View HTML